The company reported record annual revenue of $4.27 billion for 2025, driven by strong launches and growth in key products. It resolved major legal issues, extending the commercial lifespan of its core drugs. Positive late-stage data for its cancer drug zanidatamab indicates it could become a new standard of care, with a potential launch in late 2026. A major analyst initiated coverage with an Overweight rating and a $224 price target, citing strength in its neuroscience portfolio.